A Cost Per Responder Analysis of Secukinumab Vs. Adalimumab Based on a Matching-Adjusted Indirect Comparison of Efficacy Data for the Treatment of Ankylosing Spondylitis at 52 Weeks from the Irish Payer Perspective

Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.759
https://www.valueinhealthjournal.com/article/S1098-3015(17)31093-8/fulltext
Section Title : Disease-Specific Studies
Section Order : 725
First Page : A533
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)31093-8&doi=10.1016/j.jval.2017.08.759
HEOR Topics :
Tags :
Regions :